---
title: "Health and Life Sciences"
id: "1909"
type: "secteur"
slug: "health-and-life-sciences"
published_at: "2026-01-20T09:51:32+00:00"
modified_at: "2026-09-04T08:09:47+00:00"
url: "https://www.august-debouzy.com/en/secteur/health-and-life-sciences/"
markdown_url: "https://www.august-debouzy.com/en/secteur/health-and-life-sciences.md"
excerpt: "0 0 Advancing Innovation, Navigating Regulation The health and life sciences sector faces a unique combination of scientific innovation, public interest, and intense regulation. Companies must navigate sector-specific rules, intellectual property issues, artificial intelligence, data security, and complex public procurement..."
taxonomy_language:
  - "English"
taxonomy_post_translations:
  - "pll_696f50248d122"
taxonomy_tax_secteur:
  - "Life sciences & Healthcare"
---

## Advancing Innovation,*Navigating Regulation*

The health and life sciences sector faces a unique combination of scientific innovation, public interest, and intense regulation. Companies must navigate sector-specific rules, intellectual property issues, artificial intelligence, data security, and complex public procurement requirements. Each product or technology must meet demanding regulatory standards while maintaining its strategic and commercial value.

We support our clients through every stage of development. Our comprehensive approach anticipates regulatory obligations, protects innovation, negotiates industrial partnerships, structures fundraising, and secures data flows. Each project benefits from cross-disciplinary expertise designed to unlock growth opportunities without compromising compliance.

Pharmaceutical companies, biotech and medtech start-ups, cosmetics manufacturers, healthcare institutions, and veterinary groups rely on us to support their development with pragmatism, agility, and technical precision.

## *our*Interventions

01

### Industrial Property

- Patent litigation and pre-litigation, valuation, licensing, and negotiations
- Drafting of contracts and patent applications for medical devices, healthcare software, and related technologies
- Patent valuation and employee invention disputes

02

### Intellectual Property

- Protection of intangible assets, designs, models, innovations, and algorithms
- Copyright protection
- Safeguarding businesses against theft or unlawful disclosure of trade secrets and confidential data
- Drafting and negotiation of confidentiality agreements, prior art searches, and license agreements
- Enforcement and defense of intellectual property rights, including anti-counterfeiting measures
- Assistance with licensing procedures

03

### European Regulation

- EU compliance, including CE marking and conformity procedures
- Compliance with the Digital Services Act (DSA)
- Relations with health authorities

04

### Healthcare Regulation

- Advertising rules for medical devices and pharmaceuticals
- Reimbursement of medical services
- Advice on clinical trials and medical research compliance
- Guidance on anti-gift and transparency regulations
- Representation before supervisory authorities such as ANSM and ARS

05

### Corporate and M&A

- Legal structuring, shareholders’ agreements, equity participation, and support for entrepreneurial projects
- Identification of investors, negotiation and planning of financing rounds, and due diligence

06

### Competition Law

- Compliance with antitrust and competition rules
- Representation before competition authorities and courts
- Merger control and concentration procedures

07

### Commercial and International Contracts

- Drafting of supply and distribution agreements
- Vendor selection, supplier contracts, and negotiation of specific clauses including termination, warranty, and liability
- International expansion and partnerships, including marketplace integration and AI-based platform agreements
- Pricing strategies

08

### Technology, Digital, and Data Protection

- Data hosting requirements for health-related personal data
- GDPR and French Data Protection Act compliance
- Data flow mapping and risk assessment

09

### Litigation and Alternative Dispute Resolution

- Handling of litigation and dispute resolution in the health sector
- Managing liability risks arising from patient harm linked to artificial intelligence
- Negotiation of contractual warranty clauses in B2B agreements for AI research and deployment

## Contact Us

## *Latest* News

[27/08/26 Deal 1 min August Debouzy advises Etherna Immunotherapies on its combination with Valerio Therapeutics to accelerate the development of targeted RNA-based therapies August Debouzy advised Etherna Immunotherapies on its proposed acquisition by Valerio Therapeutics. The €30 million transaction, supported by a €40.25 million PIPE financing, will create an integrated biotechnology company focused on RNA-based medicines.](https://www.august-debouzy.com/en/deal/august-debouzy-advises-etherna-immunotherapies-on-its-combination-with-valerio-therapeutics-to-accelerate-the-development-of-targeted-rna-based-therapies/)

[16/06/26 Deal 1 min August Debouzy advises Clariane on its exit from VivaSon and the shareholding reorganisation of the hearing care brand August Debouzy a accompagné Clariane dans le cadre de la cession de sa participation minoritaire au capital du groupe VivaSon, enseigne française indépendante d’audioprothèse.](https://www.august-debouzy.com/en/deal/august-debouzy-advises-clariane-on-its-exit-from-vivason-and-the-shareholding-reorganisation-of-the-hearing-care-brand/)

[12/12/25 Legal Article 6 min Pharma Package – Deal at the EU level on a major pharma reform The European Parliament and the Council of the EU have reached a provisional agreement on the Pharma Package, the most significant overhaul of EU pharmaceutical law in the past twenty years. The reform introduces a new directive and regulation that update regulatory data protection rules, expand the Bolar exemption, strengthen obligations on medicine supply and market continuity, and create a new transferable exclusivity voucher to incentivize priority antibiotic development. The…](https://www.august-debouzy.com/en/legal-article/pharma-package-deal-at-the-eu-level-on-a-major-pharma-reform/)

[10/09/25 Legal Article 10 min UPC Court of Appeal Clarifies Standards for Imminent Infringement in Pharmaceutical Patent Disputes The UPC Court of Appeal clarifies imminent infringement in pharma cases, overturning Boehringer v. Zentiva ruling and aligning with EU case law.](https://www.august-debouzy.com/en/legal-article/upc-court-of-appeal-clarifies-standards-for-imminent-infringement-in-pharmaceutical-patent-disputes/)

[28/05/25 Legal Article 4 min The LD Lisbon Offers Some Limited Insight on Imminent Threat of Infringement On 8 May 2025, the Lisbon Local Division of the Unified Patent Court (“UPC”) issued an order (Boehringer Ingelheim International GmbH v. Zentiva Portugal LDA, Lisbon LD, 8 May 2025, UPC_CFI_41/2025) denying a preliminary injunction application filed by Boehringer Ingelheim International GmbH (“Boehringer”) against Zentiva Portugal LDA (“Zentiva”).](https://www.august-debouzy.com/en/legal-article/the-ld-lisbon-offers-some-limited-insight-on-imminent-threat-of-infringement/)

01

05

Précédent     Suivant

[Find our latest news](https://www.august-debouzy.com/en/hub/)
News